Research at 69热视频 has brought promising developments in gene therapy targeting a rare hereditary disease present in Quebec.
Initially identified in the Charlevoix and Saguenay regions in 2000, Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) significantly affects motor control and co-ordination, and causes stiffness, particularly in the legs. This condition first appears in children ages two to five and progresses slowly. Though rare, affecting only one in 1,500 people in the region and with roughly 320 cases in Quebec, ARSACS is increasingly recognized globally as the second most common form of ataxia.
The limited number of people affected by ARSACS often makes generating interest from pharmaceutical companies a significant challenge. However,聽, including ARSACS; this aligns with the ongoing efforts of researchers such as聽Benoit Gentil, an Associate Professor in the Department of Kinesiology and Physical Education at 69热视频.
Research efforts and innovative solutions in gene therapy
Interested in diseases affecting nerves and mobility, Gentil and his research group aim to better understand ARSACS, driven by its impact in Quebec. Their research has been聽聽and has led to promising developments in gene therapy.
鈥淎RSACS is caused by a single gene called SACS,鈥� said Gentil. 鈥淲e鈥檝e developed a gene therapy that targets the root cause of the disease and aims to restore the affected gene鈥檚 function.鈥�
In gene therapy, the goal is to treat or prevent diseases by introducing new or modified genes into a patient鈥檚 cells, which are delivered through modified viruses, called 鈥渧ectors.鈥� The use of vectors ensures that the genetic instructions reach the target cells safely, efficiently and in a controlled way to minimize side effects.
鈥淭he challenge with ARSACS is that the affected gene is too large to fit into the vector we use,鈥� explained Gentil. 鈥淭o solve this, we created a 鈥榤ini gene鈥� (which we call 鈥榤ini-SACS鈥�) by finding and using only the essential parts of the gene needed to fight the disease.鈥� This method is similar to the ones used for other genetic disorders, like Duchenne muscular dystrophy.
鈥淓arly studies have shown that we can delay the onset of several symptoms of ARSACS in animal models,鈥� said Gentil. 鈥淭hese results encourage us to continue testing to see how effective the therapy can be.鈥�
Support and commercialization
Gentil said his aim is to develop and bring this technology to market. To do this, he sought the support of聽NeuroSphere, the 69热视频 platform dedicated to innovation and partnership in neuroscience and neuroinformatics research.
In addition to receiving one of NeuroSphere鈥檚聽Ignite Grants, Gentil and his team received guidance from NeuroSphere in designing experiments that meet U.S. Food and Drug Administration (FDA) requirements to ensure that the team had the necessary data for regulatory approval, to speed up the regulatory approval process.
鈥淭he strategic guidance offered by NeuroSphere has been invaluable in transitioning our research from the lab to clinical applications,鈥� said Gentil. 鈥淭hey helped us navigate aspects of intellectual property, explore partnerships with pharmaceutical companies and even potentially start a company.鈥�
NeuroSphere recently announced a strategic partnership with the Ataxia Charlevoix-Saguenay Foundation, with each group committing $200,000 to support Gentil鈥檚 research. Adrienne Crampton, Associate Director of Business Development at NeuroSphere, said that Gentil鈥檚 project stands out for its potential to make a strong impact in its field.
鈥淲hile working with Gentil鈥檚 team in the earlier stages of their research, we were impressed with their dedication and meticulous approach. Their work not only pushes the boundaries of what is possible in gene therapy for ARSACS, but also exemplifies the core mission of NeuroSphere: to drive forward transformative medical breakthroughs,鈥� said Crampton. 鈥淏y supporting projects like this, we鈥檙e investing in a future where innovative research translates into real-world clinical applications, offering hope and improved outcomes for patients.鈥�
